Biomerica Reports Fiscal 2025 Results with Operating Expense Reductions and Resilient Portfolio Performance

Biomerica reported net sales of $5.3 million for FY25, a modest decrease from $5.4 million in the prior year. Gross profit was $498,000, compared to $611,000 in the prior year. Operating expenses declined by $1.3 million, resulting in an improved operating loss of $5.1 million, a 19% year-over-year improvement. The company achieved $1.3 million in operating expense reductions and reduced cash used in operating activities to $3.8 million.

Biomerica, Inc. (NASDAQ: BMRA) reported its fiscal year 2025 (FY25) results, highlighting a 19% year-over-year improvement in operating loss despite a modest decline in revenue. The company reported net sales of $5.3 million, down from $5.4 million in the prior year, with gross profit at $498,000 compared to $611,000 in FY24 [1].

Key achievements include a $1.3 million reduction in operating expenses, with selling, general, and administrative expenses (SG&A) declining from $5.5 million to $4.6 million, and research and development (R&D) expenses falling from $1.5 million to $1.0 million. These cost reductions resulted in an operating loss of $5.1 million, a significant improvement from the prior year's $6.4 million [1].

The company also achieved a notable reduction in cash used in operating activities, decreasing from $5.3 million to $3.8 million, a $1.5 million improvement. This improvement in cash preservation extends Biomerica's runway while pursuing commercialization initiatives [1].

Biomerica's strategic growth drivers include inFoods® IBS reimbursement, expansion of EZ Detect™ in the Middle East and North Africa (MENA) region, and sales of the H. pylori antigen test in the U.S. and Europe. The company received a Proprietary Laboratory Analyses (PLA) code for inFoods® IBS, which supports Medicare and Medicaid reimbursement and broader patient access [1].

Regulatory and intellectual property achievements further bolster Biomerica's commercial foundation. The company secured EU IVDR certification for food-intolerance diagnostic tests and obtained three new international patents for inFoods® technology applications in gastrointestinal conditions [1].

Despite the 2% revenue decline, Biomerica's fiscal 2025 results demonstrate meaningful cost discipline amid challenging revenue conditions. The company's disciplined approach to cost management and strategic growth initiatives position it for future success [1].

References:
[1] https://www.stocktitan.net/news/BMRA/biomerica-reports-fiscal-2025-year-end-5aokza8x4glk.html